SCHEMBL19283638

SCHEMBL19283638

N#CCNC(=O)CC(Nc1nc2ccccc2[nH]1)c1cccc(OC(F)(F)F)c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MTOR P42345 1/20 0.46
▸ RAB9A P51151 7/20 0.43
▸ NPC1 O15118 6/20 0.43
▸ SMN1; SMN2 Q16637 4/20 0.43
▸ HTT P42858 1/20 0.43
▸ GPR139 Q6DWJ6 1/20 0.43
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ PKM P14618 2/20 0.42
▸ ALDH1A1 P00352 1/20 0.40
▸ TP53 P04637 1/20 0.40
▸ ALOX12 P18054 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.39
▸ MAPT P10636 3/20 0.39
▸ LMNA P02545 1/20 0.39
▸ LIPG Q9Y5X9 1/20 0.38
▸ BCHE P06276 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ ABL1 P00519 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20743025 0.89 MTOR (0.49) MTORRAB9ANPC1SMN1; SMN2HTT
SCHEMBL19283672 0.88 MTOR (0.47) MTORRAB9ANPC1SMN1; SMN2HTT
SCHEMBL19283808 0.88 ITGA5 (0.47) MTORRAB9ANPC1SMN1; SMN2HTT
SCHEMBL19283580 0.87 MTOR (0.46) MTORRAB9ANPC1SMN1; SMN2HTT
SCHEMBL19283670 0.83 MTOR (0.42) MTORRAB9ANPC1SMN1; SMN2HTT
SCHEMBL19283567 0.83 MTOR (0.42) MTORRAB9ANPC1SMN1; SMN2HTT
SCHEMBL30410997 0.82 MTOR (0.48) MTORRAB9ANPC1SMN1; SMN2HTT
SCHEMBL20764736 0.82 MTOR (0.48) MTORRAB9ANPC1SMN1; SMN2HTT
SCHEMBL19283879 0.81 NPC1 (0.44) RAB9ANPC1SMN1; SMN2HTTMEN1
SCHEMBL20792222 0.78 MTOR (0.46) MTORRAB9ANPC1SMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11274092-B2 Potassium channel inhibitors ACESION PHARMA APS (DK) 2022-03-15 — — US claimed
US-20210188804-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2021-06-24 — — US claimed
CN-109153667-B Novel potassium channel inhibitors 阿塞西翁制药公司 2021-04-02 — — CN claimed
EP-3419973-B1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2020-04-08 — — EP claimed
US-11274092-B2 Potassium channel inhibitors ACESION PHARMA APS (DK) 2022-03-15 — — US disclosed
US-20210188804-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2021-06-24 — — US disclosed
US-20210188804-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2021-06-24 — — US disclosed
CN-109153667-B Novel potassium channel inhibitors 阿塞西翁制药公司 2021-04-02 — — CN disclosed
EP-3419973-B1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2020-04-08 — — EP disclosed
EP-3419973-A1 NOVEL POTASSIUM CHANNEL INHIBITORS Acesion Pharma ApS (DK) 2019-01-02 — — EP disclosed
WO-2017144183-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2017-08-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210188804-A1 NOVEL POTASSIUM CHANNEL INHIBITORS KCNJ2, KCNN2, KCNN1 MTOR 1774/4885RAB9A 1632/4885NPC1 277/4885
US-11274092-B2 Potassium channel inhibitors KCNJ2, KCNJ11, KCNJ1 MTOR 2223/4885RAB9A 1920/4885NPC1 268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback